Skip to main content

KEEP THEM PROTECTED WITH ONE SIMPLE DOSE

KEEP THEM PROTECTED WITH ONE SIMPLE DOSE

Esperoct® is an extended half-life (EHL) rFVIII that keeps dosing simple.1

ROUTINE PROPHYLAXIS: 4 DAYS TO THE NEXT DOSE

For patients ≥12 years of age

The recommended dose of Esperoct® is 50 IU/kg every 4 days.

With the extended half-life of Esperoct®, your patients may need up to 50% fewer infusionsb per year compared to standard half-life rFVIII treatments.

This regimen may be individually adjusted to less or more frequent dosing1,a

aBased on bleeding episodes.
b50% fewer if previously dosed every other day; 40% fewer if previously dosed 3x/week.

Esperoct® also may be dosed to achieve a specific target Factor VIII activity level, depending on the severity of hemophilia, for on-demand treatment/control of bleeding episodes, or perioperative management.

To achieve a specific target Factor VIII activity level, use the following formula:
Dosage (IU) = Body Weight (kg) × Desired Factor VIII Increase (IU/dL or % normal) × 0.5

With the extended half-life of Esperoct®, your patients may need up to 50% fewer infusionsb per year compared to standard half-life rFVIII treatments.

MASAC recommends prophylaxis for patients with severe hemophilia A.

MASAC recommends that prophylaxis be considered optimal therapy for individuals with severe hemophilia A (factor VIII or <1%). Prophylactic therapy should be instituted early (prior to the onset of frequent bleeding), with the aim of keeping the trough FVIII level above 1% between doses.2

MASAC=Medical and Scientific Advisory Council, National Hemophilia Foundation

DOSING FOR TREATMENT OF BLEEDING EPISODES

For patients ≥12 years of age

Esperoct® provides effective bleed control with 1 simple dose.1

cAdditional dose can be administered every 24 hours for major or life-threatening bleeding.1

DOSING FOR PERIOPERATIVE MANAGEMENT

For patients ≥12 years of age

Esperoct® provides effective perioperative control with 1 simple dose.1

dFor minor surgeries, additional dose(s) can be administered after 24 hours; for major surgeries, additional doses can be administered every 24 hours in the first week and then every 48 hours in the second week.1

DOSING FOR ROUTINE PROPHYLAXIS

For patients <12 years of age

The recommended dose of Esperoct® is 65 IU/kg twice weekly.

With the extended half-life of Esperoct®, your pediatric patients may need up to 43% fewer infusionsa per year compared to standard half-life dosing regimens.3

  • Because the clearance of FVIII products may be higher in children <12 years compared to adolescents/adults, higher and more frequent dosing may be required1

a43% fewer if previously dosed every other day; 33% fewer if previously dosed 3x/week.

Esperoct® also may be dosed to achieve a specific target Factor VIII activity level, depending on the severity of hemophilia, for on-demand treatment/control of bleeding episodes, or perioperative management.

To achieve a specific target Factor VIII activity level, use the following formula:
Dosage (IU) = Body Weight (kg) × Desired Factor VIII Increase (IU/dL or % normal) × 0.5

With the extended half-life of Esperoct®, your pediatric patients may need up to 43% fewer infusionsa per year compared to standard half-life dosing regimens.3

MASAC recommends prophylaxis for patients with severe hemophilia A.

MASAC recommends that prophylaxis be considered optimal therapy for individuals with severe hemophilia A (factor VIII or <1%). Prophylactic therapy should be instituted early (prior to the onset of frequent bleeding), with the aim of keeping the trough FVIII level above 1% between doses.2

MASAC=Medical and Scientific Advisory Council, National Hemophilia Foundation

DOSING FOR TREATMENT OF BLEEDING EPISODES

For patients <12 years of age

The recommended dose of Esperoct® to control bleeding episodes in children is 65 IU/kg.1

bAdditional dose can be administered every 24 hours for major or life-threatening bleeding.1

DOSING FOR PERIOPERATIVE MANAGEMENT

For patients <12 years of age

The recommended dose of Esperoct® for perioperative management in children is 65 IU/kg.1

cFor minor surgeries, additional dose(s) can be administered after 24 hours; for major surgeries, additional doses can be administered every 24 hours in the first week and then every 48 hours in the second week.1

AVAILABLE IN MULTIPLE VIAL SIZES

Esperoct® is supplied in single-dose vials with color-coded caps to differentiate the dose strengths.1

Esperoct® multiple vial sizes
Esperoct® multiple vial sizes

ROOM TEMPERATURE STABLE UP TO 104˚F FOR UP TO 3 MONTHS

Esperoct® requires no refrigeration and can be stored at temperatures up to 104˚F for up to 3 months or 86˚F for up to 12 months.1

Post-reconstitution, Esperoct® can be stored for use within 4 hours at up to 86˚F.1

Please see Prescribing Information for complete storage instructions.

Count on the proven safety profile of Esperoct®.

Reconstitute in just a few steps.

Esperoct® attach, twist, mix

With MixPro®, it’s as quick as attach, twist, and mix.1

Register to get the latest updates about Esperoct®

Register to get the latest updates about Esperoct®

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information

References:

  1. Esperoct [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.
  2. National Hemophilia Foundation. MASAC recommendations concerning prophylaxis, #241. New York, NY: National Hemophilia Foundation; 2016.
  3. Cafuir L and Kempton C. Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hem. 2017;8(10):303–313.